Cyclope Bio SL

Cyclope Bio SL, a for-profit chemical manufacturer based in Spain, supplies specialized organic compounds and research services to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) as a sole-source purchase-order prime contractor, competing without small-business set-asides. The vendor operates under NAICS 325199 (All Other Basic Organic Chemical Manufacturing) and PSC 6810 (Chemicals).

Cyclope Bio's federal work centers on the synthesis and delivery of custom cyclopentane and tetrahydrofuran diamine enantiomers in support of NIDDK's Synthetic Bioactive Molecules Section. These compounds serve as precursor materials for thyclotide diagnostic probe development and cyclopentane peptide nucleic acid synthesis, with applications in HIV detection, prevention, and treatment research funded by the NIH Office of AIDS Research. Recent awards include a $99 thousand purchase order (July 2024) for enantiomers of cyclopentane diamine and tetrahydrofuran diamine; a $140 thousand purchase order (September 2025) for 100-gram quantities of three distinct enantiomers and research services to develop routes to pyrrolidine analogs; and an $80 thousand purchase order (August 2026) for 200 grams of (1S,2S)-trans-N-Boc-1,2-cyclopentanediamine. All awards specified sole-source or incumbent-contractor status and were structured as simplified-acquisition requests for quotation with performance in Spain.

Customer concentration is absolute — NIDDK accounts for all three awards and the full $319 thousand in combined potential value across the vendor's tracked federal footprint. Two of the three awards face ultimate completion within the next twenty-four months (combined potential value $220 thousand), representing the full recompete exposure window. Cyclope Bio holds no seats on government-wide vehicles, BPAs, or multi-agency IDIQs; all activity to date flows through individual purchase orders issued directly by NIDDK.